MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

f	OIPE Substitut	e for form 1449B.	/PTO	Complete if Known		
Λ	RIFORM	ATION DISCLO	SURE	Application Number	09/679,147	
•	S\$ATEM	ENT BY APPLI	CANT	Filing Date	10/5/2000	
•	MAY 1 3 2004 500 Sub	mittade May 19	2004	First Named Inventor	Tomoki TODO	
줩.	K	mitted: May 12	, 2004	Group Art Unit	1632	
_	as mai	ny sheets as ne	cessary)	Examiner Name	Anne Marie Sabrina Wehbe	
E	SHEEDER! ART	of	1	Attorney Docket Number	066683-0190	

				U.S. PATENT DOCUMENTS		
		U.S. Patent Document			Date of Publication of	Pages, Columns, Lines, Where Relevant
Examiner Initials*	Cite No. <sup>1</sup>	Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear

				F	DREIGN PATENT DOCUMEN	TS		
Examiner Initials*	Cite No.1	Fore Office <sup>3</sup>	eign Patent D Number <sup>4</sup>	ocument Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	τ <sup>¢</sup>
								<u> </u>
		-		<del></del>			·	<del> </del>

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposlum, catalog, etc.) date, page(s), volume-issue number(s) publisher, city and/or country where published.			
NF	<b>3</b> 1	FIELDS et al, B7.1 is a Quantitatively Stronger Costimulus Than B7.2 in the Activation of Naïve CD8 <sup>+</sup> TCR-Transgenic T Cells, The American Association Immunologists, 1998, pp. 161: 5269-5275			
1,	A2	KWON et al., Elimination of Residual Metastatic Prostate Cancer After Surgery and Adjunctive Cytotoxic T Lymphocyte-associated Antigen 4 (CTLA-4) Blockade Immunotherapy, PNAS, December 21, 1999, pp. 15074-15079, Vol. 96, No. 26			
	АЗ	HENRY et al., Structure and Evolution of the Extended B7 Family, Review Immunology Todaym, June 1999, pp. 285-288, Vol. 20, No. 6			
-					

Examiner Signature	NUL	Date Considered	7/22/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>2</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.